Claudine Prowse

Claudine Prowse

No más puestos en curso

Health Technology
Finance
Consumer Services

Perfil

Claudine Prowse worked as an Executive Director of Corporate Development at Ionis Pharmaceuticals, a Research Analyst at CIBC World Markets Corp., a Vice President of Investor Relations at Human Genome Sciences, a Vice President of Investor Relations and Planning at Biogen, a Vice President of Strategy and Investor Relations at Inotek Pharmaceuticals Corp., a Research Analyst at Oppenheimer & Co., a Senior VP of Communications and Investor Relations at Kite Pharma, and a Vice President and Product Manager at Leerink Swann & Co. and MEDACorp, Inc. She also worked as a Senior VP of Strategy and Corporate Development at Rocket Pharmaceuticals, Inc. She received an undergraduate degree from the University of California San Diego and a graduate degree from UC San Diego School of Medicine.

Antiguos cargos conocidos de Claudine Prowse.

EmpresasCargoFin
ROCKET PHARMACEUTICALS, INC. Contacto de Relaciones con Inversores 01/08/2021
Analyst-Equity 31/01/2008
Analyst-Equity 13/01/2008
MEDACorp, Inc. Corporate Officer/Principal -
Leerink Swann & Co. Corporate Officer/Principal -
Ver el detalle de la experiencia de Claudine Prowse.

Formación de Claudine Prowse.

University of California San Diego Undergraduate Degree
UC San Diego School of Medicine Graduate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Claudine Prowse.

Relaciones

86

Relaciones de 1er grado

12

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas3
BIOGEN INC.

Health Technology

IONIS PHARMACEUTICALS, INC.

Health Technology

ROCKET PHARMACEUTICALS, INC.

Health Technology

Empresas privadas7

Finance

Health Technology

Health Technology

Finance

Health Technology

Leerink Swann & Co.

Finance

MEDACorp, Inc.

Commercial Services

Ver las conexiones de la empresa
-40% Prolongación excepcional: Nuestras suscripciones le guían hacia las mejores inversiones del mañana.
APROVÉCHELO AHORA